Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer

Published:2017-02-06 Issue:6 Volume:83 Page:1216-1226
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Brown Kathryn¹,Comisar Craig²,Witjes Han²,Maringwa John²,de Greef Rik²,Vishwanathan Karthick³,Cantarini Mireille⁴,Cox Eugène²

Affiliation:

1. UCB; Slough UK

2. Quantitative Solutions, a Certara company; Breda The Netherlands

3. AstraZeneca; Waltham USA

4. AstraZeneca, Alderley Park; UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13223/fullpdf

Reference11 articles.

1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands;Southan;Nucl Acids Res,2016

2. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes;Alexander;Br J Pharmacol,2015

3. AZD9291, an irreversible EGFR TKI, overcomes T790 M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

4. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer;Jänne;N Engl J Med,2015

5. AZD9291 in treatment-naive EGFRm advanced NSCLC: AURA first-line cohort. Presented in mini oral session, WCLC Denver 6-9 September 2015;Ramalingam;J Thorac Oncol,2015

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure–response modelling of osimertinib in patients with non‐small cell lung cancer;British Journal of Clinical Pharmacology;2024-08-19

2. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II;Critical Reviews in Oncology/Hematology;2024-08

3. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC);Bioorganic & Medicinal Chemistry;2024-07

4. Systematic Evaluation of Osimertinib Population Pharmacokinetic Models in a Cohort of Dutch Adults with Non-Small Cell Lung Cancer;European Journal of Drug Metabolism and Pharmacokinetics;2024-06-15

5. Integrated PBPK-EO modeling of osimertinib to predict plasma concentrations and intracranial EGFR engagement in patients with brain metastases;Scientific Reports;2024-06-03